2019-11-14T17:46:40-06:00 2018-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2018-01-01 352577906 MAXAID MAXA 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2019-11-14 1 JANE M SEARING P00000565 4254544919 2019-11-14 65.158.230.194 2019-11-14 11:06:05 PS P DE1D2BBAE0F1147E7A7EA18DABEA7E867F199504 2DE068ACBFA10A31F139242116409E8904B6E6F4 2018 2020-03-31 21:24:44Z PATRICIA M PEARCE 1107 NE 45TH NO 230 SEATTLE WA 98105 295408696 0 X WWW.MAXAID.ORG X 2016 WA MAXAID IS A 501(C)(3) NON-PROFIT THAT WAS SET UP BY THE MAX FOUNDATION AS A SUBSIDIARY TO SUPPORT ITS MISSION OF INCREASING GLOBAL ACCESS TO TREATMENT, CARE, AND SUPPORT FOR PEOPLE LIVING WITH CANCER. 7 6 0 7 0 0 177650543 295396811 0 0 0 0 21375 11885 177671918 295408696 36413085 248436769 0 0 0 0 0 0 0 2897324 4919379 39310409 253356148 138361509 42052548 139136934 182220385 775425 1806328 138361509 180414057 X MAXAID IS A 501(C)(3) NON-PROFIT THAT WAS SET UP BY THE MAX FOUNDATION AS A SUBSIDIARY TO SUPPORT ITS MISSION OF INCREASING GLOBAL ACCESS TO TREATMENT, CARE, AND SUPPORT FOR PEOPLE LIVING WITH CANCER. THE PRIMARY PURPOSE OF MAXAID IS TO CARRY OUT TREATMENT ACCESS SOLUTIONS FOR ONCOLOGY PRODUCTS IN LOW-AND-MIDDLE INCOME COUNTRIES IN PARTNERSHIP WITH THE MAX FOUNDATION. 0 0 253355009 248436769 11885 FROM ITS LAUNCH, MAXAID HAS HOSTED THE MAX FOUNDATION'S COLLABORATION WITH NOVARTIS, A LEADING GLOBAL HEALTHCARE COMPANY, AROUND HUMANITARIAN ACCESS TO THEIR MEDICINES GLIVEC AND TASIGNA IN A JOINT INITIATIVE KNOWN AS CMLPATH TO CARE. IN 2018, THE COLLABORATION ENABLED THOUSANDS OF PATIENTS IN LOW AND MIDDLE INCOME COUNTRIES TO ACCESS MUCH NEEDED ONCOLOGY PRODUCTS THAT THEY WOULD NOT HAVE OTHERWISE BEEN ABLE TO ACCESS. ACCESS TO MEDICINES WAS ENABLED THROUGH THE MAX FOUNDATION'S PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. IN THE CASE OF MAXAID, ONCOLOGY PRODUCTS WERE RECEIVED FROM THE DRUG MANUFACTURER NOVARTIS AND CHANNELED TO INIDVIDUAL PATIENTS VIA THE MAX FOUNDATION'S NETWORK OF HEALTHCARE PROVIDERS AND TREATMENT CENTERS. 253355009 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 X PATRICIA GARCIA-GONZALEZ 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PAULA BOULTBEE PRESIDENT 2.00 5.00 X X 0 0 0 DAVID TINGSTAD SECRETARY 2.00 2.00 X X 0 0 0 JERRY SCOTT CPA TREASURER 2.00 5.00 X X 0 0 0 ROBERT FARMER BOARD MEMBER 2.00 2.00 X 0 0 0 TRACEY HIGGINS BOARD MEMBER 2.00 2.00 X 0 0 0 GRANT RUBENSTEIN BOARD MEMBER 2.00 5.00 X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 2.00 5.00 X 0 0 0 PATRICIA GARCIA-GONZALEZ CEO 5.00 50.00 X X 0 207685 14993 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 2.00 40.00 X X 0 66887 4654 0 274572 19647 0 0 1 0 THE MAX FOUNDATION 1107 NE 45TH NO 230 SEATTLE WA 98105 PROFESSIONAL SERVICES 2551500 TANNER PHARMA CH GMBH ALTE STEINHAUSERSTRASSE 21 CHAM SZ 6330 PROFESSIONAL SERVICES 2366740 2 295396811 288381805 295396811 REIMBURSABLE FEES 900099 11885 11885 11885 295408696 11885 0 0 248436769 248436769 898 898 4918240 4918240 241 241 253356148 253355009 1139 0 644577 661056 0 634980 138492297 180402686 60 521663 139136934 182220385 124697 50600 0 240000 650728 1515728 775425 1806328 X 0 11371 138361509 180402686 138361509 180414057 139136934 182220385 42052548 0 X 0 1 X 1 0 X X X 1 THE MAX FOUNDATION 911893957 7 1 2551500 248436769 1 2551500 248436769 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 DUE TO MAX FOUNDATION 1515728 1515728 1 CENTRAL AMERICA AND THE CARIBBEANEAST ASIA AND THE PACIFICNORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 14795510 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION 9399419 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 1408314 RUSSIA AND THE NEWLY INDEPENDENT STATES 0 0 GRANTS TO RECIPIENTS IN REGION 17538700 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 57826209 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS IN REGION 9136510 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 25998413 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 112333694 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 0 0 0 0 0 0 248436769 0 248436769 DRUG CENTRAL AMERICA AND THE CARIBBEANEAST ASIA AND THE PACIFICMIDDLE EAST 1243 14678465 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA & THE PACIFIC 570 9325061 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 100 1397173 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICA 742 17399954 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 3176 57368753 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 894 9064232 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 1886 25792743 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 6116 111445036 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 0 0 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CEO 0 197685 0 10000 0 0 0 0 0 14993 0 222678 0 0 PART I, LINE 3 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. X 18410970 288381805 COMM VOL AVG WHOLESALE 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUTED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE SEVEN VOLUNTEER BOARD MEMBERS. FORM 990, PART VI, SECTION A, LINE 8B DUE TO THE SIZE OF THE ORGANIZATION, COMMITTEES ARE NOT DEEMED NECESSARY BY THE MAXAID BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 15 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART VI, LINES 12, 13 AND 14: MAXAID FOLLOWS THE CONFLICT OF INTEREST, DOCUMENT RETENTION AND WHISTLEBLOWER POLICIES OF ITS SUPPORTED ORGANIZATION, THE MAX FOUNDATION. THE MAX FOUNDATION 1107 NE 45TH NO 230 SEATTLE WA 98105 911893957 EXPAND HUMANITARIAN ACCESS TO TREATMENTS FOR CANCER WA 501(C)(3) LINE 10 0 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF TO SUPPORT THE MAX FOUNDATION SF MAX FOUNDATION T 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0